The Effects of Valsartan and Amlodipine on the Levels of Irisin, Adropin, and Perilipin

Basit Öğe Kaydı
dc.contributor.authorCelik, Huseyin Tugrul
dc.contributor.authorAkkaya, Nermin
dc.contributor.authorErdamar, Husamettin
dc.contributor.authorGok, Sumeyye
dc.contributor.authorKazanci, Fatmanur
dc.contributor.authorDemircelik, Bora
dc.contributor.authorCakmak, Muzaffer
dc.date.accessioned2025-10-24T18:10:14Z
dc.date.available2025-10-24T18:10:14Z
dc.date.issued2015
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractBackground: Hypertension and obesity are two major threats for public health. Up to the present, antihypertensive medications have been used to lower blood pressure, which seem to provide a better life with lower morbidity and mortality rates. Their effect on etiopathogenesis of hypertension is now an area of developing research. The association between hypertension and obesity also suggests the link between antihypertensive agents and energy hemostasis. We aimed to investigate the effects of antihypertensive treatment on the irisin, adropin, and perilipin levels in patients with essential hypertension and to compare them with healthy volunteers in terms of their effect on energy hemostasis. Methods: In total, 85 newly diagnosed patients with untreated essential hypertension were admitted to the outpatient clinic. Patients were randomized to one of the following treatment protocols: amlodipine or valsartan for a 12 week period. 42 patients were randomized into the valsartan group and 43 patients into the amlodipine group. Serum perilipin, irisin, and adropin levels were measured before and after drug treatment by ELISA kits. Results: We discovered that the hypertensive patients have lower levels of perilipin and higher levels of adropin compared with the control group. Both amlodipine and valsartan increased the levels of perilipin, irisin, and adropin after 12 weeks of treatment. Conclusions: In conclusion, in regulating energy balance, perilipin, irisin, and adropin, could be of pathogenic importance in obesity-induced hypertension. Hence, ongoing trials need to elucidate this mechanism.
dc.identifier.doi10.7754/Clin.Lab.2015.150420
dc.identifier.endpage1895
dc.identifier.issn1433-6510
dc.identifier.issue12
dc.identifier.pmid26882812
dc.identifier.scopus2-s2.0-84961047341
dc.identifier.scopusqualityQ3
dc.identifier.startpage1889
dc.identifier.urihttps://doi.org/10.7754/Clin.Lab.2015.150420
dc.identifier.urihttps://hdl.handle.net/20.500.12899/4055
dc.identifier.volume61
dc.identifier.wosWOS:000367771200011
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherClin Lab Publ
dc.relation.ispartofClinical Laboratory
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20251023
dc.subjectadropin; irisin; energy homeostasis; antihypertensive treatment; perilipin
dc.titleThe Effects of Valsartan and Amlodipine on the Levels of Irisin, Adropin, and Perilipin
dc.title.alternativeThe effects of valsartan and amlodipine on the levels of irisin, adropin, and perilipin
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu